 DUBLIN, March 11, 2021 PRNewswire -- Alkermes plc Nasdaq: ALKS today announced that nemvaleukin alfa nemvaleukin, formerly referred to as ALKS 4230, the companys investigational engineered interleukin-2 IL-2 variant immunotherapy, has been granted orphan drug designation for the treatment of mucosal melanoma by the U.S. Food and Drug Administration FDA. This orphan drug designation is an important milestone for the nemvaleukin alfa program and underscores nemvaleukins potential clinical utility in mucosal melanoma, a particularly aggressive form of melanoma for which treatment options remain limited, said Jessicca Rege, Ph.D. 